Official website: peptidecheck.nlIndependent · sells nothing · no medical claims · Check the address bar. We are independent and not affiliated with the sellers listed, sell nothing, make no medical claims and sellers do not pay for their position.
Peptide Check

Background

Why the Dutch inspectorate warns about peptide sellers

The Dutch Health and Youth Care Inspectorate (IGJ) warns about peptides bought online because no one can guarantee what is in the vial. A second question also plays a role: do the same rules protect the market of large pharmaceutical companies? Both are true, but they do not carry equal weight.

What the IGJ says

In February 2026 the inspectorate warned that peptides bought online can have serious or even fatal consequences. The core of that warning: you do not know what you are getting, where it comes from or what it does.

In August 2026 the first hard measure followed. The IGJ ordered web shop Peptidekoning to stop trading in retatrutide, tirzepatide and semaglutide. The inspectorate gives three reasons:

  • Retatrutide is an experimental medicine without a marketing authorisation; its long-term safety is still being studied.
  • The inspectorate received reports of harm after use of retatrutide and of counterfeit tirzepatide and semaglutide.
  • The seller did not have the permits required to trade and supply medicines.

According to the IGJ, a label such as "for research use only" changes nothing: selling medicines without a permit remains prohibited. Consumer programme Kassa pointed out that such products are often delivered with injection needles and alcohol swabs.

The health risks

The risks of a peptide bought online sit at three levels. A lab report only touches the first.

  1. What is in the vial. The wrong substance, too much or too little, or contamination with another peptide. Our own checks show that a large share of offers has no verifiable report, and that some reports come from labs that cannot be found as companies.
  2. Whether it is safe to inject. Bacteria and endotoxins (bacterial remnants that can cause fever and shock) can cause infections or severe reactions. Registered injectables are made sterile under supervision; for these products no one knows how they were filled.
  3. What the substance does in the body. Retatrutide is still in clinical trials. The right dose, side effects and long-term effects have not been established. No vial, however pure, solves that.

On top of that, users dose without a doctor and have to recognise side effects without guidance. That is why the Dutch Medicines Act routes sales through pharmacies and doctors.

Does market protection play a role?

Critics of the policy point out that the same rules that protect patients also shield the market of large manufacturers. Their arguments:

  • Approval is expensive and slow. Only a company that can pay for years of clinical trials obtains a marketing authorisation. Small players cannot get in.
  • Exclusivity. In the EU a new medicine gets, besides patents, 8 years of data protection plus 2 years of market protection. During that period no one else may sell it.
  • Big interests. Retatrutide is being developed by Eli Lilly; semaglutide and tirzepatide are the best-selling medicines of Novo Nordisk and Lilly. Cheap versions from China undermine that revenue, even before retatrutide is on the market.
  • Selective attention. The first order concerned exactly these three GLP-1 medicines, not for example BPC-157 or GHK-Cu.

On the other hand:

  • The IGJ is a government body and is not paid by the industry. The Medicines Act also applies to small and generic manufacturers.
  • The inspectorate bases its order on reports of harm and counterfeit products, not on lost revenue.
  • That enforcement started with GLP-1 medicines also fits the risk: they are used most, by the largest and least experienced group of buyers.
  • A product without approval is not cheaper because it is just as good, but because no one pays to show that it is safe.

So the honest answer is: yes, the system also protects markets, and that is a fair point for debate. But it does not make the health risks any smaller. The two explanations do not exclude each other.

What a lab report does and does not cover

A seller will never say it sells poor products. That is why a verifiable lab report is the best a buyer has. It reduces some of the risks, but not all.

RiskStandard report (HPLC and MS)With extra testsNot solvable by any test
Wrong substanceYes
Too much or too little mgYes
Contamination with another peptidePartlyLC-MS screening
Bacteria in the vialNoSterility test
EndotoxinsNoEndotoxin test
Heavy metalsNoICP-MS
Dose, side effects, long termNoOnly clinical trials

Two caveats. A report covers one sample from one batch; the vial you buy may come from another batch. And most reports sellers show only include HPLC and MS, so nothing about sterility or endotoxins: exactly the risks that matter most when injecting.

Conclusion

The IGJ's warning is first and foremost about health, and those concerns are justified. That the approval system also protects the market of large manufacturers is a legitimate point for debate, but no reason to ignore the risks.

For those who buy anyway, quality makes a difference. A report you can check with the lab itself, with the right substance and amount, is far better than a promise without proof. It does not make a product safe, but it does make it more verifiable. That is what Peptide Check is for: not to recommend peptides, but to show which sellers can back up their claims.

Peptide Check gives no medical advice. If you are considering a medicine such as semaglutide or tirzepatide, discuss it with a doctor; they are available through the pharmacy.

Warning from Peptide Check

Unreliable seller

Our advice Choose a seller with a green tick: it has a report you can check with the lab itself.
Continue anyway